Ambit Biosciences Corporation and Astellas Pharma Inc. announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. This partnership includes AC220, Ambit’s lead clinical-stage investigational drug that entered into a Phase 2 clinical trial earlier this month in relapsed/refractory acute myeloid leukemia (AML), and other undisclosed FLT3 kinase inhibitors…

View original here: 
Ambit Biosciences And Astellas Enter Strategic Partnership To Research, Develop And Commercialize FLT3 Kinase Inhibitors In Multiple Indications

Related posts:

1. Ambit Biosciences Initiates First Phase 2 Clinical Trial Of AC220 In Acute Myeloid LeukemiaAmbit Biosciences Corporation announced the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2...
2. Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher’s Disease TreatmentPfizer (NYSE: PFE) and Protalix (NYSE-Amex: PLX) today announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in...
3. In Strategic Plan For Autism Research IACC Includes Vaccine Research ObjectiveAutism Speaks is encouraged by the decision of the Interagency Autism Coordinating Committee (IACC) to include vaccine research studies in the objectives of the updated Strategic Plan for Autism Research....
4. BD Biosciences Announces First Winners Of Expanded Research Grant ProgramBD Biosciences, a segment of BD (Becton, Dickinson and Company), announced the first seven winners of its expanded BD Biosciences Research Grant Program who will receive research reagents valued at...
5. Astellas Award For Blindness Prevention Research Received By University Of Maryland ChemistFredrick Khachik, Ph.D., a senior research scientist in the Department of Chemistry and Biochemistry at the University of Maryland, College Park, has been chosen to receive a 2009 Astellas USA...
6. Predictive Biosciences Presents Novel Multi-Analyte Approach To Diagnostic Assay Development At Annual Meeting Of The Society Of Urologic OncologyPredictive Biosciences today announced that Company scientists will be presenting a novel multi-analyte approach to the development of a non-invasive, urine-biomarker based diagnostic assay during the 10th Annual Meeting of...
7. Carfilzomib Demonstrates Encouraging Response Rates In Patients With Relapsed And/or Refractory Multiple Myeloma In An Ongoing Phase 2 StudyOnyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib. Results demonstrated promising overall response...
8. AGRA, NEPAD Agree To Partnership To Expand Food Security In AfricaThe Alliance for a Green Revolution in Africa (AGRA) has entered into an "historic" partnership with the New Partnership for Africa's Development (NEPAD) "to work towards increasing food production and...
9. Combination Therapy With Midostaurin Improves Survival Of AML Patients With FLT3 MutationsA targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at...
10. Astellas Award For Arsenic Groundwater Remediation Efforts Received By Lehigh University ProfessorArup K. SenGupta, Ph.D., a professor of civil, environmental and chemical engineering at Lehigh University in Bethlehem, Pa., has been chosen to receive a 2009 Astellas USA Foundation Award. The...
11. Sangamo BioSciences Announces Presentation Of Preliminary Data From Phase 2 Study Of SB-509 At International ALS SymposiumSangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic...
12. Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United StatesTheravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S. ...
13. Linkage Biosciences Unveils LinkSeqTM — A Revolutionary New Tool For Immunogenetic TestingLinkage Biosciences, Inc., a privately held molecular diagnostics company, recently unveiled LinkSeq™ -- a new one-step method for Human Leukocyte Antigen (HLA) testing -- at the annual meeting of the...
14. Amarillo Biosciences Comments On New Findings Of H1N1 In Animals And Potential Effect On Human InfectionsAmarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) reported that the American Veterinary Medical Association (AVMA) recently confirmed that a household cat in Iowa developed signs of respiratory infection caused by H1N1...
15. Sangamo BioSciences Provides Update On Phase 1 Safety Trial Of SB-728-T For HIV/AIDSSangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS...